EmBase |
No. |
Search |
Hits |
#80 |
#19 AND #47 AND #78 |
12,819 |
#79 |
#21 AND #47 AND #78 |
|
#78 |
#48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 |
|
#77 |
‘questionnaire’/exp |
|
#76 |
‘interview’/exp |
|
#75 |
‘experience’/exp |
|
#74 |
‘perception’/exp |
|
#73 |
‘health personnel attitude’/exp |
|
#72 |
‘attitude’/exp |
|
#71 |
‘use of’ |
|
#70 |
‘survey*’ |
|
#69 |
‘questionnaire*’ |
|
#68 |
‘interview*’ |
|
#67 |
‘focus group*’ |
|
#66 |
‘facilitator*’ |
|
#65 |
‘enabler*’ |
|
#64 |
‘challenge*’ |
|
#63 |
‘barrier*’ |
|
#62 |
‘believe’ |
|
#61 |
‘belief*’ |
|
#60 |
‘experience*’ |
|
#59 |
‘value’ |
|
#58 |
‘perception*’ |
|
#57 |
perceive |
|
#56 |
adoption |
|
#55 |
implementation |
|
#54 |
‘comprehension’ |
|
#53 |
understand*’ |
|
#52 |
‘opinion*’ |
|
#51 |
‘health personnel attitude’ |
|
#50 |
‘attitude*’ |
|
#49 |
‘perspective*’ |
|
#48 |
‘view*’ |
|
#47 |
#22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 |
|
#46 |
‘psychosis’/exp |
|
#45 |
‘schizophrenia’/exp |
|
#44 |
‘bipolar disorder’/exp |
|
#43 |
‘anxiety disorder’/exp |
|
#42 |
‘major depression’/exp |
|
#41 |
‘mood stabilizer’ |
|
#40 |
‘mood stabiliser’ |
|
#39 |
‘antipsychotic*’ |
|
#38 |
‘antidepressant*’ |
|
#37 |
‘psychotic’ |
|
#36 |
‘psychosis’ |
|
#35 |
‘schizophren*’ |
|
#34 |
‘bipolar*’ |
|
#33 |
‘affective*’ |
|
#32 |
‘anxiety’ |
|
#31 |
‘depress*’ |
|
#30 |
‘mood disorder’/exp |
|
#29 |
‘mood disorder’ |
|
#28 |
‘psychiatry’/exp |
|
#27 |
‘psychiatr*’ |
|
#26 |
‘mental disease’/exp |
|
#25 |
‘mental health*’ |
|
#24 |
‘mental disorder’ |
|
#23 |
‘mental disease’ |
|
#22 |
‘mental illness’ |
|
#21 |
#19 OR #20 |
|
#20 |
#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 |
|
#19 |
#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 |
|
#18 |
‘genetic screening’/exp |
|
#17 |
‘genetic information’ |
|
#16 |
‘genetic variation’ |
|
#15 |
‘genetic profile’ |
|
#14 |
‘genetic variant*’ |
|
#13 |
‘genetic test*’ |
|
#12 |
personalized medicine’/exp |
|
#11 |
‘precision prescribing’ |
|
#10 |
‘precision medicine’ |
|
#9 |
‘personali*ed prescribing’ |
|
#8 |
‘personalized medicine’ |
|
#7 |
‘personalised medicine’ |
|
#6 |
‘pharmacogenetic testing’/exp |
|
#5 |
‘pharmacogen* test*’ |
|
#4 |
‘pharmacogenetics’/exp |
|
#3 |
‘pharmacogenetic*’ |
|
#2 |
‘pharmacogenomics’/exp |
|
#1 |
‘pharmacogenomic*’ |
|
Medline |
#79 |
S12 AND S49 AND S77 |
7400 |
#78 |
S21 AND S49 AND S77 |
16,920 |
#77 |
S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 |
|
#76 |
“use of” |
|
#75 |
“survey” |
|
#74 |
(MH “Surveys and Questionnaires”) |
|
#73 |
“questionnaire” |
|
#72 |
(MH “Focus Groups”) |
|
#71 |
“focus group*” |
|
#70 |
“interview*” |
|
#69 |
“facilitator*” |
|
#68 |
“enabler*” |
|
#67 |
“challenge*” |
|
#66 |
“barrier*” |
|
#65 |
“believe” |
|
#64 |
“belief*” |
|
#63 |
“experience*” |
|
#62 |
“value” |
|
#61 |
“perception*” |
|
#60 |
(MH “Perception”) |
|
#59 |
“perceive” |
|
#58 |
“adoption” |
|
#57 |
(MH “Implementation Science”) |
|
#56 |
“implementation” |
|
#55 |
“understand*” |
|
#54 |
“opinion*” |
|
#53 |
(MH “Attitude of Health Personnel”) OR (MH “Attitude”) |
|
#52 |
“attitude*” |
|
#51 |
“perspective*” |
|
#50 |
“view*” |
|
#49 |
S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 |
|
#48 |
“mood stabiliser*” |
|
#47 |
(MH “Antipsychotic Agents”) |
|
#46 |
“antipsychotic*” |
|
#45 |
(MH “Serotonin and Noradrenaline Reuptake Inhibitors”) OR (MH “Selective Serotonin Reuptake Inhibitors”) |
|
#44 |
(MH “Antidepressive Agents, Tricyclic”) OR (MH “Antidepressive Agents”) |
|
#43 |
“antidepressant*” |
|
#42 |
(MH “Psychotic Disorders”) |
|
#41 |
(MH “Schizophrenia”) OR (MH “Schizophrenia, Catatonic”) OR (MH “Schizophrenia, Paranoid”) OR (MH “Schizophrenia, Treatment-Resistant”) OR (MH “Schizophrenia Spectrum and Other Psychotic Disorders”) |
|
#40 |
(MH “Bipolar Disorder”) OR (MH “Bipolar and Related Disorders”) |
|
#39 |
(MH “Anxiety”) OR (MH “Anxiety Disorders”) |
|
#38 |
(MH “Depression”) OR (MH “Depressive Disorder, Treatment-Resistant”) OR (MH “Depressive Disorder”) OR (MH “Depressive Disorder, Major”) OR (MH “Depression, Chemical”) |
|
#37 |
“psychotic*” |
|
#36 |
“psychosis” |
|
#35 |
“schizophren*” |
|
#34 |
“bipolar” |
|
#33 |
“anxiety” |
|
#32 |
“depress*” |
|
#31 |
(MH “Mood Disorders”) OR (MH “Bipolar Disorder”) OR (MH “Affective Disorders, Psychotic”) |
|
#30 |
“mood disorder” |
|
#29 |
(MH “Psychiatry”) |
|
#28 |
“psychiatr*” |
|
#27 |
(MH “Mental Health”) OR (MH “Mental Health Services”) |
|
#26 |
(MH “Mental Disorders”) |
|
#25 |
“mental health*” |
|
#24 |
“mental disease” |
|
#23 |
“mental disorder” |
|
#22 |
“mental illness” |
|
#21 |
S12 OR S20 |
|
#20 |
S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 |
|
#19 |
(MH “Pharmacogenomic Variants”) OR (MH “Genetic Variation”) OR (MH “Polymorphism, Genetic”) |
|
#18 |
(MH “Genetic Testing”) |
|
#17 |
“genetic information” |
|
#16 |
“genetic screening” |
|
#15 |
“genetic variation” |
|
#14 |
“genetic variant*” |
|
#13 |
“genetic test*” |
|
#12 |
S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 |
|
#11 |
(MH “Precision Medicine”) |
|
#10 |
“precision prescribing” |
|
#9 |
“personalized prescribing” |
|
#8 |
“personalised prescribing” |
|
#7 |
“precision medicine” |
|
#6 |
“personalised medicine” |
|
#5 |
“personalized medicine” |
|
#4 |
(MH “Pharmacogenetics”) OR (MH “Pharmacogenomic Testing”) OR (MH “Pharmacogenomic Variants”) |
|
#3 |
“pharmacogenetic test*” |
|
#2 |
“pharmacogenetic*” |
|
#1 |
“pharmacogenomic*” |
|
PsycInfo |
No. |
Term |
Hits |
S73 |
S15 AND S48 AND S71 |
2680 |
S72 |
S22 AND S48 AND S71 |
|
S71 |
S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 |
|
S70 |
(((((DE “Attitudes”) OR (DE “Perception”)) AND (DE “Semi-Structured Interview” OR DE “Focus Group Interview” OR DE “Interviews”)) OR (DE “Focus Group”)) OR (DE “Surveys”)) OR (DE “Questionnaires”) |
|
S69 |
“use of” |
|
S68 |
survey* |
|
S67 |
questionnaire |
|
S66 |
“focus group*” |
|
S65 |
interview* |
|
S64 |
facilitator* |
|
S63 |
enabler* |
|
S62 |
challenge* |
|
S61 |
barrier* |
|
S60 |
believe |
|
S59 |
belief* |
|
S58 |
experience* |
|
S57 |
value |
|
S56 |
perceive |
|
S55 |
adoption |
|
S54 |
implementation |
|
S53 |
understand* |
|
S52 |
opinion* |
|
S51 |
attitude* |
|
S50 |
perspective* |
|
S49 |
view* |
|
S48 |
S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 |
|
S47 |
“mood stabili*er” |
|
S46 |
DE “Affective Disorders” |
|
S45 |
DE “Tricyclic Antidepressant Drugs” OR DE “Antidepressant Drugs” OR DE “Serotonin Norepinephrine Reuptake Inhibitors” |
|
S44 |
DE “Neuroleptic Drugs” OR DE “Neuroleptic Malignant Syndrome” OR DE “Psychotropic Drugs” |
|
S43 |
antidepressant* |
|
S42 |
antipsychotic* |
|
S41 |
DE “Psychosis” |
|
S40 |
DE “Schizophrenia” OR DE “Schizophrenia (Disorganized Type)” OR DE “Childhood Onset Schizophrenia” OR DE “Undifferentiated Schizophrenia” OR DE “Process Schizophrenia” OR DE “Paranoid Schizophrenia” OR DE “Catatonic Schizophrenia” OR DE “Acute Schizophrenia” OR DE “Schizophreniform Disorder” OR DE “Schizoaffective Disorder” |
|
S39 |
DE “Bipolar Disorder” OR DE “Bipolar I Disorder” OR DE “Bipolar II Disorder” OR DE “Mood Stabilizers” |
|
S38 |
DE “Anxiety” OR DE “Anxiety Disorders” OR DE “Generalized Anxiety Disorder” |
|
S37 |
DE “Major Depression” OR DE “Depression (Emotion)” OR DE “Postpartum Depression” OR DE “Reactive Depression” OR DE “Treatment Resistant Depression” OR DE “Bipolar Disorder” OR DE “Late Life Depression” OR DE “Recurrent Depression” OR DE “Endogenous Depression” OR DE “Atypical Depression” OR DE “Long-term Depression (Neuronal)” OR DE “Seasonal Affective Disorder” |
|
S36 |
psychotic |
|
S35 |
psychosis |
|
S34 |
schizophren* |
|
S33 |
bipolar |
|
S32 |
anxiety |
|
S31 |
depressi* |
|
S30 |
DE “Mental Health” OR DE “Mental Health Services” |
|
S29 |
DE “Psychiatry” |
|
S28 |
“mood disorder” |
|
S27 |
psychiatr* |
|
S26 |
“mental health*” |
|
S25 |
“mental disease” |
|
S24 |
“mental disorder” |
|
S23 |
“mental illness” |
|
S22 |
S15 OR S21 |
|
S21 |
S16 OR S17 OR S18 OR S19 OR S20 |
|
S20 |
DE “Genetic Testing” |
|
S19 |
“genetic information” |
|
S18 |
“genetic screen*” |
|
S17 |
“genetic varia*” |
|
S16 |
“genetic test*” |
|
S15 |
S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 |
|
S14 |
DE “Precision Medicine” |
|
S13 |
“personalized prescribing” |
|
S12 |
“personalized medicine” |
|
S11 |
“precision prescribing” |
|
S10 |
“precision medicine” |
|
S9 |
“personalised prescribing” |
|
S8 |
“personalised medicine” |
|
S7 |
DE “Pharmacogenetics” |
|
S6 |
“pharmacogenomic testing” |
|
S5 |
“pharmacogenetic testing” |
|
S4 |
pharmacogenetic* |
|
S3 |
pharmacogenetics |
|
S2 |
pharmacogenomic* |
|
S1 |
Pharmacogenomics |
|
Scopus |
No. |
Term |
Hits |
S73 |
((TITLE-ABS-KEY (“view*”)) OR (TITLE-ABS-KEY (“perspective*”)) OR (TITLE-ABS-KEY (“attitude*”)) OR (TITLE-ABS-KEY (“opinion*”)) OR (TITLE-ABS-KEY (“understand*”)) OR (TITLE-ABS-KEY (“implementation”)) OR (TITLE-ABS-KEY (“adoption”)) OR (TITLE-ABS-KEY (“perceive”)) OR (TITLE-ABS-KEY (“value”)) OR (TITLE-ABS-KEY (“experience*”)) OR (TITLE-ABS-KEY (“belief*”)) OR (TITLE-ABS-KEY (“believe”)) OR (TITLE-ABS-KEY (“barrier*”)) OR (TITLE-ABS-KEY (“challenge*”)) OR (TITLE-ABS-KEY (“enabler*”)) OR (TITLE-ABS-KEY (“facilitator*”)) OR (TITLE-ABS-KEY (“interview*”)) OR (TITLE-ABS-KEY (“focus group*”)) OR (TITLE-ABS-KEY (“questionnaire”)) OR (TITLE-ABS-KEY (“survey*”))) AND (((TITLE-ABS-KEY (“precision prescribing”)) OR (TITLE-ABS-KEY (“precision medicine”)) OR (TITLE-ABS-KEY (“personalized prescribing”)) OR (TITLE-ABS-KEY (“personalised prescribing”)) OR (TITLE-ABS-KEY (“personalized medicine”)) OR (TITLE-ABS-KEY (“personalised medicine”)) OR (TITLE-ABS-KEY (“pharmacogenomic testing”)) OR (TITLE-ABS-KEY (“pharmacogenetic testing”)) OR (TITLE-ABS-KEY (pharmacogenetic*)) OR (TITLE-ABS-KEY (pharmacogenetics)) OR (TITLE-ABS-KEY (pharmacogenomic*)) OR (TITLE-ABS-KEY (pharmacogenomics))) AND ((TITLE-ABS-KEY (“mental illness”)) OR (TITLE-ABS-KEY (“mental disorder”)) OR (TITLE-ABS-KEY (“mental disease”)) OR (TITLE-ABS-KEY (“mental health”)) OR (TITLE-ABS-KEY (“psychiatr*”)) OR (TITLE-ABS-KEY (“mood disorder”)) OR (TITLE-ABS-KEY (“depressi*”)) OR (TITLE-ABS-KEY (“anxiety”)) OR (TITLE-ABS-KEY (“bipolar”)) OR (TITLE-ABS-KEY (“schizophren*”)) OR (TITLE-ABS-KEY (“psychosis”)) OR (TITLE-ABS-KEY (“psychotic”)) OR (TITLE-ABS-KEY (“affective”)) OR (TITLE-ABS-KEY (“antipsychotic*”)) OR (TITLE-ABS-KEY (“antidepressant*”)) OR (TITLE-ABS-KEY (“mood stabili*er*”)))) |
5246 |
Description: in the table is the full searching strategy used during in the review. |